180
Participants
Start Date
September 30, 2005
Primary Completion Date
January 31, 2009
Study Completion Date
June 30, 2012
Etanercept
Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].
Mycophenolate Mofetil
Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].
Denileukin Diftitox
Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].
Pentostatin
Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
Memorial Sloan-Kettering Cancer Center, New York
University of Pennsylvania Cancer Center, Philadelphia
Johns Hopkins/SKCCC, Baltimore
Duke University Medical Center (Peds), Durham
University of Florida College of Medicine (Shands), Gainesville
University Hospitals of Cleveland/Case Western, Cleveland
University of Michigan Medical Center, Ann Arbor
University of Minnesota, Minneapolis
Washington University/Barnes Jewish Hospital, St Louis
University of Nebraska Medical Center, Omaha
University of Texas/MD Anderson CRC, Houston
Texas Transplant Institute, San Antonio
City of Hope National Medical Center, Duarte
University of California, San Diego
Stanford Hospital and Clinics, Stanford
Oregon Health Sciences University, Portland
Fred Hutchinson Cancer Research Center, Seattle
DFCI/Brigham & Women's Hospital, Boston
Hackensack University Medical Center, Hackensack
National Heart, Lung, and Blood Institute (NHLBI)
NIH
National Cancer Institute (NCI)
NIH
Blood and Marrow Transplant Clinical Trials Network
NETWORK